| P50 | author | Raffaella Pippa | Q41553656 |
| P2093 | author name string | María D Odero | |
| | Elena Arriazu | |
| P2860 | cites work | The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR | Q22254335 |
| | Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET | Q24294337 |
| | ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ-PP2A | Q24298893 |
| | B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK | Q24303557 |
| | The tumor suppressor PP2A Abeta regulates the RalA GTPase | Q24307546 |
| | The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A | Q24310186 |
| | Identification of PP2A complexes and pathways involved in cell transformation | Q24316472 |
| | Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET | Q24318458 |
| | CIP2A inhibits PP2A in human malignancies | Q24319683 |
| | Protein kinases and phosphatases in the control of cell fate | Q24604987 |
| | Molecular Genetic Markers in Acute Myeloid Leukemia | Q26799606 |
| | Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients | Q26799609 |
| | Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms | Q73540311 |
| | Effects of regulatory subunits on the kinetics of protein phosphatase 2A | Q74311713 |
| | Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity | Q81223136 |
| | Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells | Q42583764 |
| | Inhibition of protein phosphatase 2A activity by PI3Kγ regulates β-adrenergic receptor function | Q42703429 |
| | Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. | Q42820035 |
| | Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation | Q43240765 |
| | The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. | Q43515530 |
| | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene | Q43539814 |
| | Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. | Q44320317 |
| | Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease | Q44899474 |
| | Aberrant intracellular localization of SET-CAN fusion protein, associated with a leukemia, disorganizes nuclear export | Q47236572 |
| | PP2A:B56ϵ is required for Wnt/β-catenin signaling during embryonic development | Q47590689 |
| | PP2A:B56epsilon is required for eye induction and eye field separation. | Q50643244 |
| | The Greatwall-PP2A axis in cell cycle control. | Q53044085 |
| | PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. | Q53275436 |
| | CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. | Q54393527 |
| | Protein phosphatase 2A PR130/B''alpha1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. | Q54715563 |
| | Selection of Protein Phosphatase 2A Regulatory Subunits Is Mediated by the C Terminus of the Catalytic Subunit | Q59385877 |
| | Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia | Q60623956 |
| | The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity | Q61196747 |
| | Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression | Q61776046 |
| | The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin | Q62570663 |
| | Structure of protein phosphatase methyltransferase 1 (PPM1), a leucine carboxyl methyltransferase involved in the regulation of protein phosphatase 2A activity | Q27642733 |
| | The Basic Biology of PP2A in Hematologic Cells and Malignancies | Q28088697 |
| | Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein | Q28143509 |
| | Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor | Q28182042 |
| | Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene | Q28213795 |
| | The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing | Q28215929 |
| | Identification of specific PP2A complexes involved in human cell transformation | Q28248124 |
| | Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia | Q28259037 |
| | Acute Myeloid Leukemia | Q28267442 |
| | Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 |
| | Alterations of the PPP2R1B gene in human lung and colon cancer | Q28284845 |
| | Identification of a recurrent STRN/ALK fusion in thyroid carcinomas | Q28539208 |
| | FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels | Q28541065 |
| | Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A | Q28609056 |
| | Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 |
| | Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer | Q33835127 |
| | Chronic myeloid leukemia: mechanisms of blastic transformation | Q33968037 |
| | PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length | Q33985022 |
| | PP2A: unveiling a reluctant tumor suppressor | Q34005178 |
| | From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies | Q34043449 |
| | Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers | Q34104555 |
| | CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis | Q34138056 |
| | The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells | Q34194198 |
| | PP2A:B56ϵ, a Substrate of Caspase-3, Regulates p53-dependent and p53-independent Apoptosis during Development | Q34251140 |
| | Role of serine/threonine protein phosphatase 2A in cancer | Q34305706 |
| | Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. | Q34330600 |
| | Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A | Q34516277 |
| | Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. | Q34621297 |
| | The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. | Q34707593 |
| | MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. | Q34983172 |
| | CIP2A is associated with human breast cancer aggressivity | Q34996768 |
| | Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy | Q35022139 |
| | CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma | Q39218849 |
| | Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation | Q39438493 |
| | Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. | Q39632814 |
| | PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. | Q39728074 |
| | PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation | Q39841023 |
| | SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. | Q39921977 |
| | Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. | Q40171692 |
| | The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein | Q40351786 |
| | c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. | Q40406189 |
| | A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-Ibeta in integrating chromatin hypoacetylation and transcriptional repression. | Q40557365 |
| | Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. | Q40608068 |
| | Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity | Q40944433 |
| | Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. | Q41234743 |
| | A PP1-PP2A phosphatase relay controls mitotic progression | Q41715136 |
| | Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis | Q41888954 |
| | CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes | Q42500610 |
| | CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. | Q42573854 |
| | Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia | Q35037262 |
| | Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients | Q35316765 |
| | High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia | Q35361598 |
| | SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target | Q35483640 |
| | Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia | Q35944719 |
| | FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia | Q35945171 |
| | PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice | Q36091298 |
| | The PP2A inhibitor SET regulates natural killer cell IFN-gamma production | Q36229017 |
| | FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma | Q36384629 |
| | Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A | Q36421078 |
| | Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis | Q36602177 |
| | Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes | Q36787581 |
| | Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. | Q36885712 |
| | PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells | Q37015029 |
| | PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). | Q37091364 |
| | Multiple pathways regulated by the tumor suppressor PP2A in transformation | Q37105971 |
| | Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies | Q37169105 |
| | PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells | Q37200863 |
| | Protein phosphatase 2A regulatory subunits and cancer. | Q37202956 |
| | Optimal induction and post-remission therapy for AML in first remission | Q37653235 |
| | Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer | Q37660065 |
| | Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia | Q37707099 |
| | Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications | Q37827283 |
| | Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy | Q37888917 |
| | Treatment for relapsed acute myeloid leukemia: what is new? | Q37974029 |
| | Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. | Q37979498 |
| | Protein phosphatase 2A: a target for anticancer therapy | Q38103646 |
| | Structure, regulation, and pharmacological modulation of PP2A phosphatases | Q38122081 |
| | Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. | Q38160825 |
| | The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function | Q38319012 |
| | The Interplay between PP2A and microRNAs in Leukemia | Q38370368 |
| | Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. | Q38569175 |
| | Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. | Q38941215 |
| | Silencing of STRN4 suppresses the malignant characteristics of cancer cells | Q38953772 |
| | Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity | Q38969632 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| | leukemia | Q29496 |
| P304 | page(s) | 78 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia | |
| P478 | volume | 6 | |